Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Acute Heart Failure Management

  • Cerlinskaite, Kamile (Department of Anesthesiology and Reanimation, Hopital Lariboisiere) ;
  • Javanainen, Tuija (Department of Anesthesiology and Reanimation, Hopital Lariboisiere) ;
  • Cinotti, Raphael (Department of Anesthesiology and Reanimation, Hopital Lariboisiere) ;
  • Mebazaa, Alexandre (Department of Anesthesiology and Reanimation, Hopital Lariboisiere) ;
  • behalf of the Global Research on Acute Conditions Team (GREAT) Network
  • Received : 2018.04.11
  • Accepted : 2018.05.02
  • Published : 2018.06.30
⟨ Previous Next ⟩

Abstract

Acute heart failure (AHF) is a life-threatening medical condition, where urgent diagnostic and treatment methods are of key importance. However, there are few evidence-based treatment methods. Interestingly, despite relatively similar ways of management of AHF throughout the globe, mid-term outcome in East Asia, including South Korea is more favorable than in Europe. Yet, most of the treatment methods are symptomatic. The cornerstone of AHF management is identifying precipitating factors and specific phenotype. Multidisciplinary approach is important in AHF, which can be caused or aggravated by both cardiac and non-cardiac causes. The main pathophysiological mechanism in AHF is congestion, both systemic and inside the organs (lung, kidney, or liver). Cardiac output is often preserved in AHF except in a few cases of advanced heart failure. This paper provides guidance on AHF management in a time-based approach. Treatment strategies, criteria for triage, admission to hospital and discharge are described.

Keywords

References

  1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-200. https://doi.org/10.1093/eurheartj/ehw128
  2. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013;128:e240-327. https://doi.org/10.1161/CIR.0b013e31829e8776
  3. Mebazaa A, Yilmaz MB, Levy P, et al. Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail 2015;17:544-58. https://doi.org/10.1002/ejhf.289
  4. Mebazaa A, Tolppanen H, Mueller C, et al. Acute heart failure and cardiogenic shock: a multidisciplinary practical guidance. Intensive Care Med 2016;42:147-63. https://doi.org/10.1007/s00134-015-4041-5
  5. Harjola VP, Mebazaa A, Celutkiene J, et al. Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. Eur J Heart Fail 2016;18:226-41. https://doi.org/10.1002/ejhf.478
  6. Akiyama E, Van Aelst LNL, Arrigo M, et al. East Asia may have a better 1-year survival following an acute heart failure episode compared with Europe: results from an international observational cohort. Eur J Heart Fail. 2018 [Epub ahead of print].
  7. Follath F, Yilmaz MB, Delgado JF, et al. Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Intensive Care Med 2011;37:619-26. https://doi.org/10.1007/s00134-010-2113-0
  8. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA 2002;287:628-40. https://doi.org/10.1001/jama.287.5.628
  9. Stevenson LW. Design of therapy for advanced heart failure. Eur J Heart Fail 2005;7:323-31. https://doi.org/10.1016/j.ejheart.2005.01.004
  10. Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 2003;41:1797-804. https://doi.org/10.1016/S0735-1097(03)00309-7
  11. Zannad F, Mebazaa A, Juilliere Y, et al. Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA study. Eur J Heart Fail 2006;8:697-705. https://doi.org/10.1016/j.ejheart.2006.01.001
  12. Maisel AS, Peacock WF, McMullin N, et al. Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE (Acute Decompensated Heart Failure National Registry) analysis. J Am Coll Cardiol 2008;52:534-40. https://doi.org/10.1016/j.jacc.2008.05.010
  13. Peacock WF, Emerman C, Costanzo MR, Diercks DB, Lopatin M, Fonarow GC. Early vasoactive drugs improve heart failure outcomes. Congest Heart Fail 2009;15:256-64. https://doi.org/10.1111/j.1751-7133.2009.00112.x
  14. Wuerz RC, Meador SA. Effects of prehospital medications on mortality and length of stay in congestive heart failure. Ann Emerg Med 1992;21:669-74. https://doi.org/10.1016/S0196-0644(05)82777-5
  15. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39:119-77. https://doi.org/10.1093/eurheartj/ehx393
  16. Shaefi S, O'Gara B, Kociol RD, et al. Effect of cardiogenic shock hospital volume on mortality in patients with cardiogenic shock. J Am Heart Assoc 2015;4:e001462. https://doi.org/10.1161/JAHA.114.001462
  17. Liteplo AS, Marill KA, Villen T, et al. Emergency thoracic ultrasound in the differentiation of the etiology of shortness of breath (ETUDES): sonographic B-lines and N-terminal pro-brain-type natriuretic peptide in diagnosing congestive heart failure. Acad Emerg Med 2009;16:201-10. https://doi.org/10.1111/j.1553-2712.2008.00347.x
  18. Picano E, Pellikka PA. Ultrasound of extravascular lung water: a new standard for pulmonary congestion. Eur Heart J 2016;37:2097-104. https://doi.org/10.1093/eurheartj/ehw164
  19. Al Deeb M, Barbic S, Featherstone R, Dankoff J, Barbic D. Point-of-care ultrasonography for the diagnosis of acute cardiogenic pulmonary edema in patients presenting with acute dyspnea: a systematic review and meta-analysis. Acad Emerg Med 2014;21:843-52. https://doi.org/10.1111/acem.12435
  20. Collins SP, Lindsell CJ, Storrow AB, Abraham WT; ADHERE Scientific Advisory Committee, Investigators and Study Group. Prevalence of negative chest radiography results in the emergency department patient with decompensated heart failure. Ann Emerg Med 2006;47:13-8. https://doi.org/10.1016/j.annemergmed.2005.04.003
  21. Chakko S, Woska D, Martinez H, et al. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. Am J Med 1991;90:353-9. https://doi.org/10.1016/0002-9343(91)90576-J
  22. Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014;35:3033-73. https://doi.org/10.1093/eurheartj/ehu283
  23. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1349-53. https://doi.org/10.1016/S0140-6736(97)06031-5
  24. Lassus J, Gayat E, Mueller C, et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol 2013;168:2186-94. https://doi.org/10.1016/j.ijcard.2013.01.228
  25. Felker GM, Mentz RJ, Teerlink JR, et al. Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study. Eur J Heart Fail 2015;17:1262-70. https://doi.org/10.1002/ejhf.341
  26. Peacock WF 4th, De Marco T, Fonarow GC, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008;358:2117-26. https://doi.org/10.1056/NEJMoa0706824
  27. Nikolaou M, Parissis J, Yilmaz MB, et al. Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. Eur Heart J 2013;34:742-9. https://doi.org/10.1093/eurheartj/ehs332
  28. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000;35:681-9. https://doi.org/10.1016/S0735-1097(99)00608-7
  29. Masip J, De Mendoza D, Planas K, Paez J, Sanchez B, Cancio B. Peripheral venous blood gases and pulse-oximetry in acute cardiogenic pulmonary oedema. Eur Heart J Acute Cardiovasc Care 2012;1:275-80. https://doi.org/10.1177/2048872612457087
  30. Branson RD, Johannigman JA. Pre-hospital oxygen therapy. Respir Care 2013;58:86-97. https://doi.org/10.4187/respcare.02251
  31. Masip J, Roque M, Sanchez B, Fernandez R, Subirana M, Exposito JA. Noninvasive ventilation in acute cardiogenic pulmonary edema: systematic review and meta-analysis. JAMA 2005;294:3124-30. https://doi.org/10.1001/jama.294.24.3124
  32. Plaisance P, Pirracchio R, Berton C, Vicaut E, Payen D. A randomized study of out-of-hospital continuous positive airway pressure for acute cardiogenic pulmonary oedema: physiological and clinical effects. Eur Heart J 2007;28:2895-901. https://doi.org/10.1093/eurheartj/ehm502
  33. Faris RF, Flather M, Purcell H, Poole-Wilson PA, Coats AJ. Diuretics for heart failure. Cochrane Database Syst Rev 2012:CD003838.
  34. Rochwerg B, Brochard L, Elliott MW, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J 2017;50:1602426. https://doi.org/10.1183/13993003.02426-2016
  35. Liesching T, Kwok H, Hill NS. Acute applications of noninvasive positive pressure ventilation. Chest 2003;124:699-713. https://doi.org/10.1378/chest.124.2.699
  36. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011;364:797-805. https://doi.org/10.1056/NEJMoa1005419
  37. Mentz RJ, Kjeldsen K, Rossi GP, et al. Decongestion in acute heart failure. Eur J Heart Fail 2014;16:471-82. https://doi.org/10.1002/ejhf.74
  38. Cox ZL, Lenihan DJ. Loop diuretic resistance in heart failure: resistance etiology-based strategies to restoring diuretic efficacy. J Card Fail 2014;20:611-22. https://doi.org/10.1016/j.cardfail.2014.05.007
  39. Patarroyo M, Wehbe E, Hanna M, et al. Cardiorenal outcomes after slow continuous ultrafiltration therapy in refractory patients with advanced decompensated heart failure. J Am Coll Cardiol 2012;60:1906-12. https://doi.org/10.1016/j.jacc.2012.08.957
  40. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847. https://doi.org/10.1093/eurheartj/ehs104
  41. Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 1998;351:389-93. https://doi.org/10.1016/S0140-6736(97)08417-1
  42. Packer M, O'Connor C, McMurray JJV, et al. Effect of ularitide on cardiovascular mortality in acute heart failure. N Engl J Med 2017;376:1956-64. https://doi.org/10.1056/NEJMoa1601895
  43. Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013;381:29-39. https://doi.org/10.1016/S0140-6736(12)61855-8
  44. Teerlink JR, Voors AA, Ponikowski P, et al. Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. Eur J Heart Fail 2017;19:800-9. https://doi.org/10.1002/ejhf.830
  45. Teerlink JR, Marco M. Late-breaking trials I: focus on acute heart failure. Heart Failure 2017 and the 4th World Congress on Acute Heart Failure; 2017 April 29-May 2; Paris. Paris: European Society of Cardiology; 2017 [cited 2018 Mar 22]. Available from: http://spo.escardio.org//SessionDetails.aspx?eevtid=1226&presId=154083&doc=Slides#.WrOw03_A-M8.
  46. Peacock WF, Chandra A, Char D, et al. Clevidipine in acute heart failure: Results of the A Study of Blood Pressure Control in Acute Heart Failure-A Pilot Study (PRONTO). Am Heart J 2014;167:529-36. https://doi.org/10.1016/j.ahj.2013.12.023
  47. Mebazaa A, Longrois D, Metra M, et al. Agents with vasodilator properties in acute heart failure: how to design successful trials. Eur J Heart Fail 2015;17:652-64. https://doi.org/10.1002/ejhf.294
  48. Peacock WF, Hollander JE, Diercks DB, Lopatin M, Fonarow G, Emerman CL. Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis. Emerg Med J 2008;25:205-9. https://doi.org/10.1136/emj.2007.050419
  49. Mebazaa A, Motiejunaite J, Gayat E, et al. Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long-Term Registry. Eur J Heart Fail 2018;20:332-41. https://doi.org/10.1002/ejhf.991
  50. Mortara A, Oliva F, Metra M, et al. Treatment with inotropes and related prognosis in acute heart failure: contemporary data from the Italian Network on Heart Failure (IN-HF) Outcome registry. J Heart Lung Transplant 2014;33:1056-65. https://doi.org/10.1016/j.healun.2014.05.015
  51. Mebazaa A, Parissis J, Porcher R, et al. Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods. Intensive Care Med 2011;37:290-301. https://doi.org/10.1007/s00134-010-2073-4
  52. Flaherty JD, Bax JJ, De Luca L, et al. Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment. J Am Coll Cardiol 2009;53:254-63. https://doi.org/10.1016/j.jacc.2008.08.072
  53. Kociol RD, Pang PS, Gheorghiade M, Fonarow GC, O'Connor CM, Felker GM. Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. J Am Coll Cardiol 2010;56:1071-8. https://doi.org/10.1016/j.jacc.2010.06.016
  54. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016;37:267-315. https://doi.org/10.1093/eurheartj/ehv320
  55. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36:2793-867. https://doi.org/10.1093/eurheartj/ehv316
  56. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893-962. https://doi.org/10.1093/eurheartj/ehw210
  57. European Society of Cardiology (ESC); European Heart Rhythm Association (EHRA); Brignole M, et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace 2013;15:1070-118. https://doi.org/10.1093/europace/eut206
  58. Fonarow GC, Abraham WT, Albert NM, et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med 2008;168:847-54. https://doi.org/10.1001/archinte.168.8.847
  59. Arrigo M, Tolppanen H, Sadoune M, et al. Effect of precipitating factors of acute heart failure on readmission and long-term mortality. ESC Heart Fail 2016;3:115-21. https://doi.org/10.1002/ehf2.12083
  60. Vieillard-Baron A, Caille V, Charron C, Belliard G, Page B, Jardin F. Actual incidence of global left ventricular hypokinesia in adult septic shock. Crit Care Med 2008;36:1701-6. https://doi.org/10.1097/CCM.0b013e318174db05
  61. Maisel A, Neath SX, Landsberg J, et al. Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial. Eur J Heart Fail 2012;14:278-86. https://doi.org/10.1093/eurjhf/hfr177
  62. Mockel M, Searle J, Maisel A. The role of procalcitonin in acute heart failure patients. ESC Heart Fail 2017;4:203-8. https://doi.org/10.1002/ehf2.12189
  63. Demissei BG, Cleland JG, O'Connor CM, et al. Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. Int J Cardiol 2016;204:164-71. https://doi.org/10.1016/j.ijcard.2015.11.141
  64. Fonarow GC, Adams KF, Abraham WT, et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005;293:572-80. https://doi.org/10.1001/jama.293.5.572
  65. Damman K, Navis G, Voors AA, et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 2007;13:599-608. https://doi.org/10.1016/j.cardfail.2007.04.008
  66. Dharmarajan K, Hsieh AF, Lin Z, et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA 2013;309:355-63. https://doi.org/10.1001/jama.2012.216476
  67. Gheorghiade M, Peterson ED. Improving postdischarge outcomes in patients hospitalized for acute heart failure syndromes. JAMA 2011;305:2456-7. https://doi.org/10.1001/jama.2011.836
  68. Prins KW, Neill JM, Tyler JO, Eckman PM, Duval S. Effects of beta-blocker withdrawal in acute decompensated heart failure: a systematic review and meta-analysis. JACC Heart Fail 2015;3:647-53. https://doi.org/10.1016/j.jchf.2015.03.008
  69. Khan SS, Gheorghiade M, Dunn JD, Pezalla E,, Fonarow GC. Managed care interventions for improving outcomes in acute heart failure syndromes. Am J Manag Care 2008;14:S273-86.
  70. Koelling TM, Johnson ML, Cody RJ, Aaronson KD. Discharge education improves clinical outcomes in patients with chronic heart failure. Circulation 2005;111:179-85. https://doi.org/10.1161/01.CIR.0000151811.53450.B8
  71. Harjola VP, Lassus J, Sionis A, et al. Clinical picture and risk prediction of short-term mortality in cardiogenic shock. Eur J Heart Fail 2015;17:501-9. https://doi.org/10.1002/ejhf.260
  72. Thiele H, Akin I, Sandri M, et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. N Engl J Med 2017;377:2419-32. https://doi.org/10.1056/NEJMoa1710261
  73. Levy B, Bastien O, Bendjelid K, et al. Experts' recommendations for the management of adult patients with cardiogenic shock. Ann Intensive Care 2015;5:52. https://doi.org/10.1186/s13613-015-0094-4
  74. Thiele H, Ohman EM, Desch S, Eitel I, de Waha S. Management of cardiogenic shock. Eur Heart J 2015;36:1223-30. https://doi.org/10.1093/eurheartj/ehv051
  75. Levy B, Perez P, Perny J, Thivilier C, Gerard A. Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Crit Care Med 2011;39:450-5. https://doi.org/10.1097/CCM.0b013e3181ffe0eb
  76. De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010;362:779-89. https://doi.org/10.1056/NEJMoa0907118
  77. Thiele H, Zeymer U, Neumann FJ, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012;367:1287-96. https://doi.org/10.1056/NEJMoa1208410
  78. Thiele H, Zeymer U, Neumann FJ, et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet 2013;382:1638-45. https://doi.org/10.1016/S0140-6736(13)61783-3
  79. Stretch R, Sauer CM, Yuh DD, Bonde P. National trends in the utilization of short-term mechanical circulatory support: incidence, outcomes, and cost analysis. J Am Coll Cardiol 2014;64:1407-15. https://doi.org/10.1016/j.jacc.2014.07.958
  80. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016;37:67-119. https://doi.org/10.1093/eurheartj/ehv317
  81. Arrigo M, Mebazaa A. Understanding the differences among inotropes. Intensive Care Med 2015;41:912-5. https://doi.org/10.1007/s00134-015-3659-7

Cited by

  1. Loop diuretics in chronic heart failure: how to manage congestion? vol.24, pp.1, 2018, https://doi.org/10.1007/s10741-018-9735-7
  2. A study of the predictive factors of mortality in acute poisoning with aluminum phosphide with special reference to echocardiography and SOFA score vol.26, pp.32, 2019, https://doi.org/10.1007/s11356-019-06457-4
  3. Heart failure and sepsis: practical recommendations for the optimal management vol.25, pp.2, 2018, https://doi.org/10.1007/s10741-019-09816-y
  4. Integrating Palliative Care Into Heart Failure Management vol.41, pp.3, 2018, https://doi.org/10.4037/ccn2021877
  5. A Novel Paradigm Based on ST2 and Its Contribution towards a Multimarker Approach in the Diagnosis and Prognosis of Heart Failure: A Prospective Study during the Pandemic Storm vol.11, pp.10, 2018, https://doi.org/10.3390/life11101080